Solutions - Page 2

The National Fragility Index, launched by the API Innovation Center, warned that more than 550 million prescriptions filled in the U.S. in 2023 were categorized as being highly or severely vulnerable to

For biopharmaceutical commercial teams, integrating clinical support into Patient Support Programs (PSPs) is becoming a competitive advantage for differentiating complex therapies in crowded markets.

CSL Seqirus, a unit of the Australian biopharma CSL, touted the availability of more influenza vaccines in the U.S. ahead of the impending flu season.

Bookended by its first commercial-scale manufacturing of the radioisotope actinium-225 in January and an expected high-capacity production line launch by the end of the year, radiopharmaceutical supplier and CDMO NorthStar Medical Technologies

The White House is asking pharma manufacturers to provide details on their domestic capacity as it moves forward with an initiative that will increase stateside production of 86 key medicines over the

Otsuka ICU Medical, a joint venture from Japan’s Otsuka Pharmaceutical Factory, issued a voluntary recall of one lot of 0.9% sodium chloride injection for IV due to a possible mix-up of labels.

Despite hitting a speed bump over the summer, automated cell therapy manufacturing specialist Cellares has continued to sign new partners at a steady pace, now inking a second agreement with an Asia-based

Par Health issued a voluntary recall of two lots of the IV sedative dexmedetomidine HCl in 0.9% sodium chloride injection that may be contaminated with cellulose or stopper material.

How proactive risk management, transparency and flexible communication can turn a CDMO relationship into a true strategic partnership.